200 related articles for article (PubMed ID: 12094839)
1. Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges?
Farrell RJ; Peppercorn MA
Am J Gastroenterol; 2002 Jun; 97(6):1283-5. PubMed ID: 12094839
[No Abstract] [Full Text] [Related]
2. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
3. The mesalamine wars heat up-enter balsalazide.
Cohen RD
Gastroenterology; 2003 Feb; 124(2):574-5. PubMed ID: 12557164
[No Abstract] [Full Text] [Related]
4. Treatment of ulcerative colitis with balsalazide: response to editorial by Drs. Farrell and Peppercorn and letter to the editor by Dr. Hanauer.
Johnson LK; Pruitt RE; Green JR
Am J Gastroenterol; 2003 Jan; 98(1):216-9. PubMed ID: 12526969
[No Abstract] [Full Text] [Related]
5. Oral balsalazide (Colazal) for ulcerative colitis.
Med Lett Drugs Ther; 2001 Jul; 43(1109):62-3. PubMed ID: 11468602
[No Abstract] [Full Text] [Related]
6. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
[TBL] [Abstract][Full Text] [Related]
7. Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis.
Hanauer SB
Am J Gastroenterol; 2003 Jan; 98(1):215-6. PubMed ID: 12526968
[No Abstract] [Full Text] [Related]
8. Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt.
Hanauer SB
Am J Gastroenterol; 2003 Mar; 98(3):697-8. PubMed ID: 12650813
[No Abstract] [Full Text] [Related]
9. Balsalazide disodium.
Am J Health Syst Pharm; 2002 Jan; 59(1):27. PubMed ID: 11813462
[No Abstract] [Full Text] [Related]
10. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Sandborn WJ
Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
Sandborn WJ; Hanauer SB; Buch A
Aliment Pharmacol Ther; 2004 May; 19(10):1089-98. PubMed ID: 15142198
[TBL] [Abstract][Full Text] [Related]
12. Balsalazide.
Prakash A; Spencer CM
Drugs; 1998 Jul; 56(1):83-9; discussion 90. PubMed ID: 9664201
[TBL] [Abstract][Full Text] [Related]
13. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
Green JR; Gibson JA; Kerr GD; Swarbrick ET; Lobo AJ; Holdsworth CD; Crowe JP; Schofield KJ; Taylor MD
Aliment Pharmacol Ther; 1998 Dec; 12(12):1207-16. PubMed ID: 9882028
[TBL] [Abstract][Full Text] [Related]
14. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
Green JR; Lobo AJ; Holdsworth CD; Leicester RJ; Gibson JA; Kerr GD; Hodgson HJ; Parkins KJ; Taylor MD
Gastroenterology; 1998 Jan; 114(1):15-22. PubMed ID: 9428213
[TBL] [Abstract][Full Text] [Related]
15. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
Baker DE; Kane S
Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
[TBL] [Abstract][Full Text] [Related]
16. Review article: balsalazide therapy in ulcerative colitis.
Ragunath K; Williams JG
Aliment Pharmacol Ther; 2001 Oct; 15(10):1549-54. PubMed ID: 11563993
[TBL] [Abstract][Full Text] [Related]
17. Will the real 5-aminosalicylic acid please stand up?
Regueiro MD
Inflamm Bowel Dis; 1999 May; 5(2):147-8. PubMed ID: 10338387
[No Abstract] [Full Text] [Related]
18. Efficacy of different mesalamine-releasing drugs.
Gross V
Gastroenterology; 1998 Nov; 115(5):1306-7. PubMed ID: 9797396
[No Abstract] [Full Text] [Related]
19. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
Tursi A; Brandimarte G; Giorgetti GM; Forti G; Modeo ME; Gigliobianco A
Med Sci Monit; 2004 Nov; 10(11):PI126-31. PubMed ID: 15507864
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review.
Kane SV; Bjorkman DJ
Rev Gastroenterol Disord; 2003; 3(4):210-8. PubMed ID: 14668693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
